List view / Grid view

Søren Bregenholt (Alligator Biosciences)

 

article

Targeting CD40 with bispecifics to outsmart tumours

Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how…

11 November 2024 | By

Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how creating bispecific antibodies that target both tumour-specific antigens and CD40, a receptor on the immune system’s dendritic cells, is a new approach that aims to trick tumours into telling the immune system how best to attack.